A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects.

After measles vaccine (MV), all-cause mortality is reduced more than can be explained by the prevention of measles, especially in females.We aimed to study the biological mechanisms underlying the observed non-specific and sex-differential effects of MV on mortality.Within a large randomised trial o...

Full description

Bibliographic Details
Main Authors: Kristoffer Jarlov Jensen, Mia Søndergaard, Andreas Andersen, Erliyani Sartono, Cesario Martins, May-Lill Garly, Jesper Eugen-Olsen, Henrik Ullum, Maria Yazdanbakhsh, Peter Aaby, Christine Stabell Benn, Christian Erikstrup
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4024025?pdf=render
id doaj-a45f6a87a33c4d04bd22efc39e9a5c1c
record_format Article
spelling doaj-a45f6a87a33c4d04bd22efc39e9a5c1c2020-11-24T22:03:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-0195e9753610.1371/journal.pone.0097536A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects.Kristoffer Jarlov JensenMia SøndergaardAndreas AndersenErliyani SartonoCesario MartinsMay-Lill GarlyJesper Eugen-OlsenHenrik UllumMaria YazdanbakhshPeter AabyChristine Stabell BennChristian ErikstrupAfter measles vaccine (MV), all-cause mortality is reduced more than can be explained by the prevention of measles, especially in females.We aimed to study the biological mechanisms underlying the observed non-specific and sex-differential effects of MV on mortality.Within a large randomised trial of MV at 4.5 months of age blood samples were obtained before and six weeks after randomisation to early MV or no early MV. We measured concentrations of cytokines and soluble receptors from plasma (interleukin-1 receptor agonist (IL-1Ra), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, monocyte chemoattractant protein (MCP)-1, soluble urokinase-type plasminogen activator receptor), and secreted cytokines (interferon-γ, TNF-α, IL-5, IL-10, IL-13, IL-17) after in vitro challenge with innate agonists and recall antigens. We analysed the effect of MV in multiple imputation regression, overall and stratified by sex. The majority of the infants had previously been enrolled in a randomised trial of neonatal vitamin A. Post hoc we explored the potential effect modification by neonatal vitamin A.Overall, MV versus no MV was associated with higher plasma MCP-1 levels, but the effect was only significant among females. Additionally, MV was associated with increased plasma IL-1Ra. MV had significantly positive effects on plasma IL-1Ra and IL-8 levels in females, but not in males. These effects were strongest in vitamin A supplemented infants. Vitamin A shifted the effect of MV in a pro-inflammatory direction.In this explorative study we found indications of sex-differential effects of MV on several of the plasma biomarkers investigated; in particular MV increased levels in females, most strongly in vitamin A recipients. The findings support that sex and micronutrient supplementation should be taken into account when analysing vaccine effects.clinicaltrials.gov number NCT 00168545.http://europepmc.org/articles/PMC4024025?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Kristoffer Jarlov Jensen
Mia Søndergaard
Andreas Andersen
Erliyani Sartono
Cesario Martins
May-Lill Garly
Jesper Eugen-Olsen
Henrik Ullum
Maria Yazdanbakhsh
Peter Aaby
Christine Stabell Benn
Christian Erikstrup
spellingShingle Kristoffer Jarlov Jensen
Mia Søndergaard
Andreas Andersen
Erliyani Sartono
Cesario Martins
May-Lill Garly
Jesper Eugen-Olsen
Henrik Ullum
Maria Yazdanbakhsh
Peter Aaby
Christine Stabell Benn
Christian Erikstrup
A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects.
PLoS ONE
author_facet Kristoffer Jarlov Jensen
Mia Søndergaard
Andreas Andersen
Erliyani Sartono
Cesario Martins
May-Lill Garly
Jesper Eugen-Olsen
Henrik Ullum
Maria Yazdanbakhsh
Peter Aaby
Christine Stabell Benn
Christian Erikstrup
author_sort Kristoffer Jarlov Jensen
title A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects.
title_short A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects.
title_full A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects.
title_fullStr A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects.
title_full_unstemmed A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects.
title_sort randomized trial of an early measles vaccine at 4½ months of age in guinea-bissau: sex-differential immunological effects.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description After measles vaccine (MV), all-cause mortality is reduced more than can be explained by the prevention of measles, especially in females.We aimed to study the biological mechanisms underlying the observed non-specific and sex-differential effects of MV on mortality.Within a large randomised trial of MV at 4.5 months of age blood samples were obtained before and six weeks after randomisation to early MV or no early MV. We measured concentrations of cytokines and soluble receptors from plasma (interleukin-1 receptor agonist (IL-1Ra), IL-6, IL-8, IL-10, tumor necrosis factor (TNF)-α, monocyte chemoattractant protein (MCP)-1, soluble urokinase-type plasminogen activator receptor), and secreted cytokines (interferon-γ, TNF-α, IL-5, IL-10, IL-13, IL-17) after in vitro challenge with innate agonists and recall antigens. We analysed the effect of MV in multiple imputation regression, overall and stratified by sex. The majority of the infants had previously been enrolled in a randomised trial of neonatal vitamin A. Post hoc we explored the potential effect modification by neonatal vitamin A.Overall, MV versus no MV was associated with higher plasma MCP-1 levels, but the effect was only significant among females. Additionally, MV was associated with increased plasma IL-1Ra. MV had significantly positive effects on plasma IL-1Ra and IL-8 levels in females, but not in males. These effects were strongest in vitamin A supplemented infants. Vitamin A shifted the effect of MV in a pro-inflammatory direction.In this explorative study we found indications of sex-differential effects of MV on several of the plasma biomarkers investigated; in particular MV increased levels in females, most strongly in vitamin A recipients. The findings support that sex and micronutrient supplementation should be taken into account when analysing vaccine effects.clinicaltrials.gov number NCT 00168545.
url http://europepmc.org/articles/PMC4024025?pdf=render
work_keys_str_mv AT kristofferjarlovjensen arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT miasøndergaard arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT andreasandersen arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT erliyanisartono arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT cesariomartins arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT maylillgarly arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT jespereugenolsen arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT henrikullum arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT mariayazdanbakhsh arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT peteraaby arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT christinestabellbenn arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT christianerikstrup arandomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT kristofferjarlovjensen randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT miasøndergaard randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT andreasandersen randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT erliyanisartono randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT cesariomartins randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT maylillgarly randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT jespereugenolsen randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT henrikullum randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT mariayazdanbakhsh randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT peteraaby randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT christinestabellbenn randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
AT christianerikstrup randomizedtrialofanearlymeaslesvaccineat41⁄2monthsofageinguineabissausexdifferentialimmunologicaleffects
_version_ 1725831263137300480